Jasper Therapeutics is trading 7.72% down at $0.61 after opening-market weakness on September 14, 2026, with the move most consistent with global risk-off sentiment rather than a confirmed company catalyst.
- No new company-specific announcement, earnings update, regulatory action, or analyst revision was identified; the latest official release was a September 9 conference presentation notice.
- The S&P 500 is down 0.48% and Nasdaq Composite 0.65%, amid renewed AI-slowdown concerns, higher oil prices, and Federal Reserve uncertainty.